BVXV - Nasdaq grants biondvax extension to regain compliance with listing rules

2023-08-02 07:53:24 ET

• BiondVax Pharmaceuticals ( NASDAQ: BVXV ) said Nasdaq provided an extension until October end as it reviewed the biotechnology company's multi-faceted plan to regain compliance with Nasdaq’s listing rules.
• Previously BiondVax received a deficiency letter Nasdaq notifying the company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market.
• BiondVax has provided Nasdaq with its business plan, which includes the pursuit of several non-dilutive grants, potential capital-raising transactions, and development of the company’s new CDMO business.
• Source: Press Release

For further details see: